UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 14, 2003
----------
SIGA Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-23047 13-3864870
(State or other jurisdiction of (Commission file number) (I.R.S. employer
incorporation or organization) identification no.)
420 Lexington Avenue
Suite 601
New York, New York 10170
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (212) 672-9100
ITEM 5. Other Events.
On May 15, 2003, SIGA Technologies, Inc., a Delaware corporation ("SIGA"),
issued a press release announcing that it had entered into a definitive asset
purchase agreement with Plexus Vaccine Inc., a California corporation
("Plexus"), providing for SIGA's purchase of substantially all of Plexus's
assets. A copy of the press release issued in connection with the execution of
the definitive asset agreement is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
ITEM 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
Exhibit
99.1 Press Release of SIGA Technologies, Inc. dated May 15, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SIGA Technologies, Inc.
By: /s/ Thomas N. Konatich
-------------------------------------
Name: Thomas N. Konatich
Title: Acting Chief Executive Officer and
Chief Financial Officer
Dated: May 22, 2003